Oropharyngeal Cancer - Pipeline Review, H2 2017

  • ID: 4419036
  • Report
  • 241 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • AstraZeneca Plc
  • Immunovaccine Inc
  • ISA Pharmaceuticals BV
  • Merck & Co Inc
  • Pfizer Inc
  • MORE
Oropharyngeal Cancer - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2017, provides an overview of the Oropharyngeal Cancer (Oncology) pipeline landscape.

Oropharyngeal cancer is a disease which malignant cells form in the tissue of oropharynx. Oropharynx is a middle part of the throat which includes the base of the tongue, the tonsils, the soft palate, and the walls of the pharynx. Oropharyngeal cancers can be divided into two types, HPV-positive, which are related to human papillomavirus infection, and HPV-negative cancers, which are usually linked to alcohol or tobacco use.

Report Highlights

The latest Pharmaceutical and Healthcare latest pipeline guide Oropharyngeal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oropharyngeal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Phase 0 and Preclinical stages are 1, 5, 9, 1 and 4 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Oropharyngeal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oropharyngeal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oropharyngeal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oropharyngeal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer (Oncology)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oropharyngeal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oropharyngeal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advaxis Inc
  • AstraZeneca Plc
  • Immunovaccine Inc
  • ISA Pharmaceuticals BV
  • Merck & Co Inc
  • Pfizer Inc
  • MORE
Introduction

Oropharyngeal Cancer - Overview

Oropharyngeal Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Oropharyngeal Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Oropharyngeal Cancer - Companies Involved in Therapeutics Development

Advaxis Inc

Astex Pharmaceuticals Inc

AstraZeneca Plc

Celldex Therapeutics Inc

Immunovaccine Inc

Incyte Corp

ISA Pharmaceuticals BV

Madrigal Pharmaceuticals Inc.

MedImmune LLC

Merck & Co Inc

Merck KGaA

Pfizer Inc

PNP Therapeutics Inc

Tessa Therapeutics Pte Ltd

Theralase Technologies Inc

Transgene SA

Oropharyngeal Cancer - Drug Profiles

avelumab - Drug Profile

axalimogene filolisbac - Drug Profile

BMX-001 - Drug Profile

CDX-3379 - Drug Profile

DPXE-7 - Drug Profile

durvalumab - Drug Profile

durvalumab + tremelimumab - Drug Profile

ganetespib - Drug Profile

gedatolisib - Drug Profile

gedeptin - Drug Profile

ISA-101 - Drug Profile

nimotuzumab - Drug Profile

olaparib - Drug Profile

onalespib - Drug Profile

pembrolizumab - Drug Profile

PGV-001 - Drug Profile

ruxolitinib phosphate - Drug Profile

TG-4001 - Drug Profile

TLD-1433 - Drug Profile

TT-12 - Drug Profile

utomilumab - Drug Profile

Oropharyngeal Cancer - Dormant Projects

Oropharyngeal Cancer - Discontinued Products

Oropharyngeal Cancer - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Oropharyngeal Cancer, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Oropharyngeal Cancer - Pipeline by Advaxis Inc, H2

Oropharyngeal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2

Oropharyngeal Cancer - Pipeline by AstraZeneca Plc, H2

Oropharyngeal Cancer - Pipeline by Celldex Therapeutics Inc, H2

Oropharyngeal Cancer - Pipeline by Immunovaccine Inc, H2

Oropharyngeal Cancer - Pipeline by Incyte Corp, H2

Oropharyngeal Cancer - Pipeline by ISA Pharmaceuticals BV, H2

Oropharyngeal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2

Oropharyngeal Cancer - Pipeline by MedImmune LLC, H2

Oropharyngeal Cancer - Pipeline by Merck & Co Inc, H2

Oropharyngeal Cancer - Pipeline by Merck KGaA, H2

Oropharyngeal Cancer - Pipeline by Pfizer Inc, H2

Oropharyngeal Cancer - Pipeline by PNP Therapeutics Inc, H2

Oropharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2

Oropharyngeal Cancer - Pipeline by Theralase Technologies Inc, H2

Oropharyngeal Cancer - Pipeline by Transgene SA, H2

Oropharyngeal Cancer - Dormant Projects, H2

Oropharyngeal Cancer - Discontinued Products, H2

List of Figures

Number of Products under Development for Oropharyngeal Cancer, H2

Number of Products under Development by Companies, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Routes of Administration, H2

Number of Products by Stage and Routes of Administration, H2

Number of Products by Molecule Types, H2

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Advaxis Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • Immunovaccine Inc
  • Incyte Corp
  • ISA Pharmaceuticals BV
  • Madrigal Pharmaceuticals Inc.
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Pfizer Inc
  • PNP Therapeutics Inc
  • Tessa Therapeutics Pte Ltd
  • Theralase Technologies Inc
  • Transgene SA
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll